Study S002815

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate the Efficacy and Safety of Multiple Doses of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease

ClinicalTrials.gov record

Registration

Registration: NCT07848880
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 315
Start: 2026-10
Primary completion: 2028-04
Lead sponsor: Zhejiang Doer Biologics Co., Ltd.
Conditions: Hypertriglyceridemia
Interventions: DRUG:DR10624 Injection; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Percentage change from baseline in fasting serum triglyceride concentration at Week 26 [Baseline up to Week 26 of double-blind treatment period]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.